Nav1.7 anal­gesic fail­ures stack up as Bio­gen aban­dons vixot­rig­ine af­ter lat­est set­back

A slate of drug de­vel­op­ers have re­port­ed fail­ures in tri­als test­ing Nav1.7 in­hibitors for pain man­age­ment, call­ing in­to ques­tion the promise of the class of anal­gesics. On a con­fer­ence call on Tues­day, Bio­gen dis­closed that it was aban­don­ing vixot­rig­ine for sci­at­i­ca pain af­ter the ex­per­i­men­tal drug flopped in a study, adding to a string of fail­ures al­ready di­vulged by oth­er drug­mak­ers, in­clud­ing Roche, Te­va and Xenon.

Avail­able anal­gesics – NSAIDs, amine re­up­take in­hibitors, antiepilep­tic drugs and opi­oids — of­fer vary­ing lev­els of anal­gesic ef­fi­ca­cy, and are gen­er­al­ly cou­pled with dele­te­ri­ous ef­fects. In par­tic­u­lar opi­oids — by far the most ef­fec­tive painkillers — are al­so one of the most abused class of drugs in the Unit­ed States, with ad­dic­tion lev­els and as­so­ci­at­ed deaths hit­ting epi­dem­ic pro­por­tions. With re­searchers des­per­ate­ly seek­ing oth­er av­enues to treat pain, the pro­tein Nav1.7 emerged as a vi­able can­di­date.

Nav1.7 con­trols the pas­sage of sodi­um ions in­to sen­so­ry neu­rons, and the tar­get gar­nered at­ten­tion af­ter it was found that rare hu­man mu­ta­tions char­ac­ter­ized by a loss of func­tion in Nav1.7 chan­nels re­sult­ed in con­gen­i­tal in­sen­si­tiv­i­ty to pain. But the ear­ly wave of phar­ma­ceu­ti­cal in­ter­est in Nav1.7 drug de­vel­op­ment hit a wall, in part be­cause it has been dif­fi­cult to de­sign mol­e­cules that can block just Nav1.7 and not close­ly re­lat­ed ion chan­nels that play crit­i­cal roles out­side pain sens­ing. This trend seems to have con­tin­ued this year.

Vixot­rig­ine was ac­quired by Bio­gen $BI­IB back in 2015 through its $675 mil­lion buy­out of UK-based Cov­er­gence Phar­ma­ceu­ti­cals. How­ev­er, all is not lost as the drug con­tin­ues to be eval­u­at­ed as a treat­ment for trigem­i­nal neu­ral­gia and fiber neu­ropa­thy.

On Tues­day, Bio­gen al­so an­nounced its drug, dapirolizum­ab pe­gol, which is be­ing de­vel­oped in col­lab­o­ra­tion with UCB (Eu­ronext Brus­sels: $UCB), had failed to meet the pri­ma­ry end­point in a Phase II study for lu­pus.

Mean­while, Roche’s $RHB­BY Genen­tech unit torched its Nav 1.7 in­hibitor RG6029 which was be­ing de­vel­oped un­der a 7-year-old, $646 mil­lion deal with Cana­da’s Xenon $XENE last week. Xenon’s part­ner Te­va $TE­VA al­so bowed out of its 2012 col­lab­o­ra­tion to de­vel­op a sim­i­lar in­hibitor, TV-45070, this March.

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Bahija Jallal (file photo)

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

Bahija Jallal’s crew at TCR pioneer Immunocore says they have nailed down a promising set of pivotal data for their lead drug in a frontline setting for a solid tumor. And they are framing this early interim readout as the convincing snapshot they need to prove that their platform can deliver on a string of breakthrough therapies now in the clinic or planned for it.

In advance of the Monday announcement, Jallal and R&D chief David Berman took some time to walk me through the first round of Phase III data for their lead TCR designed to treat rare, frontline cases of metastatic uveal melanoma that come with a grim set of survival expectations.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

Bob Nelsen spent his pandemic spring in his Seattle home, talking on the phone with Luciana Borio, the scientist who used to run pandemic preparedness on the National Security Council, and fuming with her about the dire state of American manufacturing.

Companies were rushing to develop vaccines and antibodies for the new virus, but even if they succeeded, there was no immediate supply chain or infrastructure to mass-produce them in a way that could make a dent in the outbreak.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Am­gen sev­ers 14-year Cy­to­ki­net­ics part­ner­ship, bail­ing on ome­cam­tiv af­ter mixed PhI­II re­sults

Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after a Phase III trial turned up weak data — leaving Cytokinetics to soldier on alone.

Omecamtiv mecarbil technically worked, meeting the primary composite endpoint in the Phase III GALACTIC-HF study. But it missed a key secondary endpoint, which analysts had been following as a key marker for success — reduction of cardiovascular (CV) death. While Cytokinetics celebrated the results, its stock tanked 43% upon the news, and analysts warned of an uncertain path ahead. Now, Amgen wants out.

Carl Hansen, AbCellera CEO (University of British Columbia)

From a pair of Air Jor­dans to a $200M-plus IPO, Carl Hansen is craft­ing an overnight R&D for­tune fu­eled by Covid-19

Back in the summer of 2019, Carl Hansen left his post as a professor at the University of British Columbia to go full time as the CEO at a low-profile antibody shop he had founded called AbCellera.

As biotech CEOs go, even after a fundraise Hansen wasn’t paid a whole heck of a lot. He ended up earning right at $250,000 for the year. His compensation package included a loan — which he later paid back — and a pair of Air Jordan tennis shoes. His newly-hired CFO, Andrew Booth, got a sweeter pay packet than that — which included his own pair of Air Jordans.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Leonard Schleifer, Regeneron CEO (Andrew Harnik/AP)

Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half after becoming the experimental treatment of choice for a newly diagnosed president, Regeneron’s antibody cocktail has received emergency use authorization from the FDA. It will be used to treat non-hospitalized Covid-19 patients who are at high-risk of progressing.

Although the Rgeneron drug is not the first antibody treatment authorized by the FDA, the news comes as a significant milestone for a company and a treatment scientists have watched closely since the outbreak began.